Systemic therapies for salivary gland cancer : Adenoid cystic carcinoma. REFCOR recommendations by the formal consensus method
Copyright © 2023 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: To determine the therapeutic indications for systemic medical treatment in the management of adenoid cystic carcinoma (ACC) according to the clinical situation.
MATERIALS AND METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group, which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: ACCs are rare tumors and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, progression is often slow. In case of oligometastatic ACC, local treatment should be discussed. The most often indolent nature of polymetastatic ACC can allow management by active surveillance. Molecular screening is recommended, for abnormalities potentially accessible to targeted therapy.
CONCLUSION: ACCs are rare tumors for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
European annals of otorhinolaryngology, head and neck diseases - (2023) vom: 06. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrand, F-R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adenoid cystic carcinoma |
|---|
| Anmerkungen: |
Date Revised 07.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.anorl.2023.11.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365528323 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365528323 | ||
| 003 | DE-627 | ||
| 005 | 20231227132342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anorl.2023.11.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM365528323 | ||
| 035 | |a (NLM)38061943 | ||
| 035 | |a (PII)S1879-7296(23)00161-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferrand, F-R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic therapies for salivary gland cancer |b Adenoid cystic carcinoma. REFCOR recommendations by the formal consensus method |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: To determine the therapeutic indications for systemic medical treatment in the management of adenoid cystic carcinoma (ACC) according to the clinical situation | ||
| 520 | |a MATERIALS AND METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group, which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method | ||
| 520 | |a RESULTS: ACCs are rare tumors and there is currently insufficient evidence to indicate chemotherapy at the localized stage. At the metastatic stage, progression is often slow. In case of oligometastatic ACC, local treatment should be discussed. The most often indolent nature of polymetastatic ACC can allow management by active surveillance. Molecular screening is recommended, for abnormalities potentially accessible to targeted therapy | ||
| 520 | |a CONCLUSION: ACCs are rare tumors for which there are currently few effective medical treatments. It is therefore recommended to include patients in clinical trials | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Adenoid cystic carcinoma | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Locally advanced stage | |
| 650 | 4 | |a Metastatic stage | |
| 650 | 4 | |a Systemic therapy | |
| 700 | 1 | |a Even, C |e verfasserin |4 aut | |
| 700 | 1 | |a Chabrillac, E |e verfasserin |4 aut | |
| 700 | 1 | |a Thariat, J |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhry, N |e verfasserin |4 aut | |
| 700 | 1 | |a Vergez, S |e verfasserin |4 aut | |
| 700 | 1 | |a Bensadoun, R-J |e verfasserin |4 aut | |
| 700 | 1 | |a Sarradin, V |e verfasserin |4 aut | |
| 700 | 1 | |a Digue, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European annals of otorhinolaryngology, head and neck diseases |d 2010 |g (2023) vom: 06. Dez. |w (DE-627)NLM201398648 |x 1879-730X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anorl.2023.11.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 12 | ||